Candidate Drug 80/5Technology Demonstration4 (Anti-dyslipidemic)
Implementing Organization
Central Research Institute (CRI)
Central Drug Research Institute (CDRI)
About
Anti-Dyslipidemic drug especially used in Dyslipidemia of Diabetes, Metabolic syndrome Obesity
For managing patients of hyperlipidemia especially triglycerides and cholesterol
The compound inhibits the biosynthesis of cholesterol and reduces the rate of cholesterol turnover. It also stimulates the LDL receptor binding activity and thereby increasing the catabolism of LDL cholesterol and significantly reduces the lipid peroxidation. It has a Triglyceride lowering activity als which is the main Lipid abnormality found in Indian population.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Central Research Institute (CRI)
Acces sibility Controls